Urogen Pharma Ltd.

Urogen Pharma Ltd. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for urological and uro-oncological diseases. The company's primary focus is on unmet medical needs within the urologic oncology space, where traditional treatment methods often fall short. Urogen Pharma utilizes its proprietary RTGel™ technology to develop drug-delivery systems that enhance the release and retention of drugs in the urinary tract, providing targeted therapies with increased efficacy and fewer systemic side effects. This platform supports their development of products for conditions such as low-grade upper tract urothelial carcinoma and non-muscle invasive bladder cancer. Urogen Pharma's pioneering approach aims to transform the treatment landscape in urology by offering more effective, non-invasive therapeutic options. Headquartered in Princeton, New Jersey, and Tamworth, UK, the company is at the forefront of significant medical advancements, helping reshape the future of urological therapies and providing critical solutions to patients and healthcare providers globally.